Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure
Abstract Background The purpose of this study is to investigate whether or not the complement system is systemically activated and to specify the clinical and prognostic implications of its components during hepatitis B virus related acute-on-chronic liver failure (HBV-ACLF). Methods Blood samples w...
| Príomhchruthaitheoirí: | , , , , , , , , |
|---|---|
| Formáid: | Alt |
| Teanga: | English |
| Foilsithe / Cruthaithe: |
BMC
2020-04-01
|
| Sraith: | BMC Gastroenterology |
| Ábhair: | |
| Rochtain ar líne: | http://link.springer.com/article/10.1186/s12876-020-01258-3 |
| _version_ | 1831848066220556288 |
|---|---|
| author | Qian Li Qing Lu Meng-Qi Zhu Chong Huang Kang-Kang Yu Yu-Xian Huang Xu Zhao Xing-Guang Luo Jian-Ming Zheng |
| author_facet | Qian Li Qing Lu Meng-Qi Zhu Chong Huang Kang-Kang Yu Yu-Xian Huang Xu Zhao Xing-Guang Luo Jian-Ming Zheng |
| author_sort | Qian Li |
| collection | DOAJ |
| description | Abstract Background The purpose of this study is to investigate whether or not the complement system is systemically activated and to specify the clinical and prognostic implications of its components during hepatitis B virus related acute-on-chronic liver failure (HBV-ACLF). Methods Blood samples were taken from twenty-seven patients diagnosed with HBV-ACLF, twenty-five patients diagnosed with chronic hepatitis B but without liver failure (CHB), and nine healthy volunteers (the control group). Plasma complement components were measured with Enzyme-linked immunosorbent assay. Correlative analysis were assessed between the levels of complement components and the liver failure related index. Results The concentrations of C3 was 6568 μg/ml in the HBV-ACLF group, 8916 μg/ml in the CHB group and 15,653 μg/ml in the control group, respectively (P < 0.05). The concentrations of C3a was 852 ng/ml in the HBV-ACLF group, 1008 ng/ml in the CHB group and 1755 ng/ml in the control group, respectively (P < 0.05). The concentrations of C1q was 50,509 ng/ml in the HBV-ACLF group, 114,640 ng/ml in the CHB group and 177,001 ng/ml in the control group, respectively (P < 0.05). The concentrations of C1q, C3, C3a, C4, C4a and sC5b-9 were significantly higher in the control group than those in the HBV-ACLF group (3.5, 2.4, 2.1, 1.4, 1.3 and 6.0 fold, respectively). However, there was no statistical significance of the differences in the plasma concentrations of mannose binding lectin and factor B between the HBV-ACLF group and control group. The levels of C3 and C3a were inversely correlated with MELDs or CLIF-C OFs (P < 0.05). Conclusions Our analysis demonstrated that the activation of the classical pathway mediated by C1q may play an important role in the pathogenesis of HBV-ACLF. Furthermore, the plasma levels of C3 and C3a may be potential novel biomarkers in predicting the outcome of HBV-ACLF. |
| first_indexed | 2024-12-23T08:29:38Z |
| format | Article |
| id | doaj.art-e3e702994aeb4924a90f87a8965b3b7f |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-12-23T08:29:38Z |
| publishDate | 2020-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-e3e702994aeb4924a90f87a8965b3b7f2022-12-21T17:53:55ZengBMCBMC Gastroenterology1471-230X2020-04-012011910.1186/s12876-020-01258-3Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failureQian Li0Qing Lu1Meng-Qi Zhu2Chong Huang3Kang-Kang Yu4Yu-Xian Huang5Xu Zhao6Xing-Guang Luo7Jian-Ming Zheng8Department of Infectious Diseases, Huashan Hospital, Fudan UniversityDepartment of Infectious Diseases, Huashan Hospital, Fudan UniversityDepartment of Infectious Diseases, Huashan Hospital, Fudan UniversityDepartment of Infectious Diseases, Huashan Hospital, Fudan UniversityDepartment of Infectious Diseases, Huashan Hospital, Fudan UniversityDepartment of Infectious Diseases, Huashan Hospital, Fudan UniversityInstitute of Antibiotics, Huashan Hospital, Fudan UniversityDepartment of Genetics, Yale University School of MedicineDepartment of Infectious Diseases, Huashan Hospital, Fudan UniversityAbstract Background The purpose of this study is to investigate whether or not the complement system is systemically activated and to specify the clinical and prognostic implications of its components during hepatitis B virus related acute-on-chronic liver failure (HBV-ACLF). Methods Blood samples were taken from twenty-seven patients diagnosed with HBV-ACLF, twenty-five patients diagnosed with chronic hepatitis B but without liver failure (CHB), and nine healthy volunteers (the control group). Plasma complement components were measured with Enzyme-linked immunosorbent assay. Correlative analysis were assessed between the levels of complement components and the liver failure related index. Results The concentrations of C3 was 6568 μg/ml in the HBV-ACLF group, 8916 μg/ml in the CHB group and 15,653 μg/ml in the control group, respectively (P < 0.05). The concentrations of C3a was 852 ng/ml in the HBV-ACLF group, 1008 ng/ml in the CHB group and 1755 ng/ml in the control group, respectively (P < 0.05). The concentrations of C1q was 50,509 ng/ml in the HBV-ACLF group, 114,640 ng/ml in the CHB group and 177,001 ng/ml in the control group, respectively (P < 0.05). The concentrations of C1q, C3, C3a, C4, C4a and sC5b-9 were significantly higher in the control group than those in the HBV-ACLF group (3.5, 2.4, 2.1, 1.4, 1.3 and 6.0 fold, respectively). However, there was no statistical significance of the differences in the plasma concentrations of mannose binding lectin and factor B between the HBV-ACLF group and control group. The levels of C3 and C3a were inversely correlated with MELDs or CLIF-C OFs (P < 0.05). Conclusions Our analysis demonstrated that the activation of the classical pathway mediated by C1q may play an important role in the pathogenesis of HBV-ACLF. Furthermore, the plasma levels of C3 and C3a may be potential novel biomarkers in predicting the outcome of HBV-ACLF.http://link.springer.com/article/10.1186/s12876-020-01258-3ComplementHepatitis B virusAcute-on-chronic liver failure |
| spellingShingle | Qian Li Qing Lu Meng-Qi Zhu Chong Huang Kang-Kang Yu Yu-Xian Huang Xu Zhao Xing-Guang Luo Jian-Ming Zheng Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure BMC Gastroenterology Complement Hepatitis B virus Acute-on-chronic liver failure |
| title | Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure |
| title_full | Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure |
| title_fullStr | Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure |
| title_full_unstemmed | Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure |
| title_short | Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure |
| title_sort | lower level of complement component c3 and c3a in the plasma means poor outcome in the patients with hepatitis b virus related acute on chronic liver failure |
| topic | Complement Hepatitis B virus Acute-on-chronic liver failure |
| url | http://link.springer.com/article/10.1186/s12876-020-01258-3 |
| work_keys_str_mv | AT qianli lowerlevelofcomplementcomponentc3andc3aintheplasmameanspooroutcomeinthepatientswithhepatitisbvirusrelatedacuteonchronicliverfailure AT qinglu lowerlevelofcomplementcomponentc3andc3aintheplasmameanspooroutcomeinthepatientswithhepatitisbvirusrelatedacuteonchronicliverfailure AT mengqizhu lowerlevelofcomplementcomponentc3andc3aintheplasmameanspooroutcomeinthepatientswithhepatitisbvirusrelatedacuteonchronicliverfailure AT chonghuang lowerlevelofcomplementcomponentc3andc3aintheplasmameanspooroutcomeinthepatientswithhepatitisbvirusrelatedacuteonchronicliverfailure AT kangkangyu lowerlevelofcomplementcomponentc3andc3aintheplasmameanspooroutcomeinthepatientswithhepatitisbvirusrelatedacuteonchronicliverfailure AT yuxianhuang lowerlevelofcomplementcomponentc3andc3aintheplasmameanspooroutcomeinthepatientswithhepatitisbvirusrelatedacuteonchronicliverfailure AT xuzhao lowerlevelofcomplementcomponentc3andc3aintheplasmameanspooroutcomeinthepatientswithhepatitisbvirusrelatedacuteonchronicliverfailure AT xingguangluo lowerlevelofcomplementcomponentc3andc3aintheplasmameanspooroutcomeinthepatientswithhepatitisbvirusrelatedacuteonchronicliverfailure AT jianmingzheng lowerlevelofcomplementcomponentc3andc3aintheplasmameanspooroutcomeinthepatientswithhepatitisbvirusrelatedacuteonchronicliverfailure |